17-hydroxyprogesterone (Duralutin, Makena, Prodrox)

Pharmacology

Tradename: Duralutin, Makena (caproate)

Indications

• treatment of amenorrhea
• abnormal uterine bleeding
• submucous fibroids
• endometriosis
• uterine carcinoma
• testing of estrogen production
• to reduce the risk for preterm labor & preterm delivery

Dosage

• amenorrhea:
  • 375 mg IM
  • if no bleeding, begin cyclic treatment with estradiol valerate
• test for endogenous estrogen production:
  • 250 mg at any time during the estrous cycle
  • bleeding 7-14 days after injection indicates positive test
• risk for preterm delivery (Makena)
  • injection into the hip once a week, beginning at 16 weeks of pregnancy, up to 21 weeks

Injection: 250 mg/mL (5 mL).

Adverse effects

• common (> 10%)
  • edema, breakthrough bleeding, spotting, changes in menstrual flow, amenorrhea, anorexia, pain at site of injection, weakness
• less common (1-10%)
  • edema, mental depression, insomnia, fever, melasma, chloasma, rash, pruritus, weight gain or loss, changes in cervical erosions & secretions, increased breast tenderness, cholestatic jaundice

More general terms

• progesterone (Progestasert, Prometrium, Pro-Gest, Prochieve)
• 17 hydroxycorticosteroid
• adrenal cortex hormone; corticosteroid
• endocrine agent

Additional terms

• 17-hydroxyprogesterone in serum/plasma
• steroid biosynthesis

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6238